DRI Healthcare Trust Acquires Royalty in Pre-Approval Sebetralstat for Up to $179 Mln

DRI Healthcare Trust bought a royalty interest in Sebetralstat, a drug for hereditary angioedema, for $179 million. The drug is in the approval process with the FDA and EMA, potentially becoming the first oral therapy for this condition.